Shanghai Pharmaceuticals' Salbutamol Sulfate Injection Passes Regulatory Consistency Evaluation

MT Newswires Live

2025/07/29

Shanghai Pharmaceuticals Holding's (SHA:601607, HKG:2607) drug supplementary application for salbutamol sulfate injection has passed the Chinese drug administration's consistency evaluation, according to a Shanghai bourse filing on Tuesday.

The drug was tested for its consistency in quality and efficacy.

The pharmaceutical company's subsidiary, Shanghai Hefeng Pharmaceutical, developed the drug to treat respiratory diseases, such as bronchial asthma and asthmatic bronchitis.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2555081810"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2555081810\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2555081810?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-29 12:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2555081810","market":"fut","top_or_hot":-1,"title":"Shanghai Pharmaceuticals' Salbutamol Sulfate Injection Passes Regulatory Consistency Evaluation","media":"MT Newswires Live","content":"<html><body><p> Shanghai Pharmaceuticals Holding's  (SHA:601607, HKG:2607) drug supplementary application for salbutamol sulfate injection has passed the Chinese drug administration's consistency evaluation, according to a Shanghai bourse filing on Tuesday.</p><p>The drug was tested for its consistency in quality and efficacy.</p><p>The pharmaceutical company's subsidiary, Shanghai Hefeng Pharmaceutical, developed the drug to treat respiratory diseases, such as bronchial asthma and asthmatic bronchitis.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Shanghai Pharmaceuticals' Salbutamol Sulfate Injection Passes Regulatory Consistency Evaluation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShanghai Pharmaceuticals' Salbutamol Sulfate Injection Passes Regulatory Consistency Evaluation\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2025-07-29 12:07</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> Shanghai Pharmaceuticals Holding's  (SHA:601607, HKG:2607) drug supplementary application for salbutamol sulfate injection has passed the Chinese drug administration's consistency evaluation, according to a Shanghai bourse filing on Tuesday.</p><p>The drug was tested for its consistency in quality and efficacy.</p><p>The pharmaceutical company's subsidiary, Shanghai Hefeng Pharmaceutical, developed the drug to treat respiratory diseases, such as bronchial asthma and asthmatic bronchitis.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0188","symbol_name":"孖展沽空","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2555081810","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2555081810","pubTimestamp":1753762079,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Shanghai Pharmaceuticals Holding's   drug supplementary application for salbutamol sulfate injection has passed the Chinese drug administration's consistency evaluation, according to a Shanghai bourse filing on Tuesday.The drug was tested for its consistency in quality and efficacy.The pharmaceutical company's subsidiary, Shanghai Hefeng Pharmaceutical, developed the drug to treat respiratory diseases, such as bronchial asthma and asthmatic bronchitis.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"601607":"上海医药","BK0188":"融资融券","BK0209":"零售","BK0012":"证金概念","BK0175":"白马股","BK0196":"行业龙头","BK0183":"MSCI概念","BK0184":"上海国资改革","BK0187":"一线龙头","BK0097":"医药电商","BK0028":"国家队","BK0099":"上海本地重组","BK1197":"保健护理产品经销商","BK0020":"浦东新区","02607":"上海医药"},"translate_title":"上海医药硫酸沙丁胺醇注射液通过监管一致性评价","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"601607":0.9,"02607":0.9},"content_text":"Shanghai Pharmaceuticals Holding's  (SHA:601607, HKG:2607) drug supplementary application for salbutamol sulfate injection has passed the Chinese drug administration's consistency evaluation, according to a Shanghai bourse filing on Tuesday.The drug was tested for its consistency in quality and efficacy.The pharmaceutical company's subsidiary, Shanghai Hefeng Pharmaceutical, developed the drug to treat respiratory diseases, such as bronchial asthma and asthmatic bronchitis.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}